3i plc, 91 Waterloo Road, London SE1 8XP, UK, Tel: +44 (0) 20 7975 3366, Fax: +44 (0) 20 7975 3241, E-mail: dina_chaya@3i.com

Revised 21 October 2004.

Abstract

Following recent difficult private and public equity markets, many biotech start-ups are now under considerable pressure. In this environment, start-ups are struggling to secure financing and their valuations are being trimmed by investors. In order to survive, firms are being compelled to adjust their business models to satisfy investors, enter alliances to decrease their cash burn and consolidate with external assets to build critical mass internally.